Evidence map›Paper›PMID 29757582›Full record

ArticleJBRA assisted reproduction2018

Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome.

Saghar Salehpour, Sedighe Hosseini, Leila Nazari, Nasrin Saharkhiz, Shahrzad Zademodarres

Open access · bronzeAbstract read
In one paragraph

Article in JBRA assisted reproduction, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Saghar SalehpourPreventative Gynecology Research Center (PGRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sedighe HosseiniPreventative Gynecology Research Center (PGRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Leila NazariPreventative Gynecology Research Center (PGRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nasrin SaharkhizPreventative Gynecology Research Center (PGRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahrzad ZademodarresPreventative Gynecology Research Center (PGRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPolycystic ovary syndrome is one of the most common endocrinopathies in young women, and it affects 6% to 8% of women in reproductive age. Hyperandrogenism is the hallmark of polycystic ovary syndrome. The aim of the present study was to evaluate the effects of orlistat on weight loss and serum androgen levels among Iranian women with polycystic ovary syndrome.

methodsThe present study was carried out in the clinic of Infertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Thirty-two patients with polycystic ovary syndrome were randomly enrolled. We measured serum androgens (Testosterone, 17α-hydroxyprogesterone, dehydroepiandrosterone and sex hormone-binding globulin) before and after 12 weeks of treatment with orlistat. We used the Rotterdam Criteria for all patients and transvaginal sonography was performed.

resultsThe mean age of patients was 27.75±6.22 and the mean body mass index was 32.69±0.94 kg/m2. Comparing with baseline, treatment with orlistat resulted in a significant reduction in weight, BMI, and waist circumference (p=0.001). We also found a remarkable reduction in total testosterone levels (p>0.001). Treatment improved the sex hormone-binding globulin plasma levels, but the improvement was not statistically significant. There was no reduction in other androgen levels.

conclusionThis study showed a significant reduction of weight and total testosterone level - the most important androgen in polycystic ovary syndrome - after 12 weeks of treatment with orlistat. Therefore, it seems that a short course of orlistat can be useful in the management of patients with polycystic ovary syndrome.

Indexed as

AdultAndrogensAnti-Obesity AgentsBody Mass IndexFemaleHumansIranObesityOrlistatPolycystic Ovary SyndromeSex Hormone-Binding GlobulinTestosteroneTreatment OutcomeWaist CircumferenceYoung AdultAndrogensAnti-Obesity AgentsOrlistatSex Hormone-Binding GlobulinTestosteroneandrogenIranorlistatPolycystic ovary syndromeweight loss

Identifiers

PMID29757582
PMCPMC6106633
OpenAlexW2894978756

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.